The Use of Antidepressants, Anxiolytics, and Hypnotics in People with Type 2 Diabetes and Patterns Associated with Use: The Hoorn Diabetes Care System Cohort
Table 1
Patients characteristics and prevalence of antidepressants, anxiolytics, and/or hypnotics use in the year 2011 from the Hoorn Diabetes Care System Cohort.
Percentage missing data
Number of patients ()
7016
Male (%)
52.2
—
Age (years)
66.3 ± 11.7 (66.6, 15.6)
—
HbA1c (mmol/mol and %)
52 (6.9) ± 1.1 (49, 1.0)
1.8%
BMI (kg/m2)
30.2 ± 5.4 (29.3, 6.7)
4.6%
Diabetes duration (years)
7.3 ± 6.6 (6.0, 9.0)
0.3%
Onset age of diabetes (years)
58.1 ± 12.1 (59.0, 16.0)
0.3%
Ethnicity (% Caucasian)
77.5
15
Education (%)
5.4
Low
43.8
Middle
37.0
High
13.8
Marriage status (%)
27.7
Married
45.5
Unmarried
5.0
Divorced
0.9
Single
7.7
Widowed
13.2
Only antidepressants use (%)
7.1
—
Only anxiolytics and/or hypnotics use (%)
6.5
—
Combination use (antidepressants and anxiolytics/hypnotics) (%)
3.6
—
Comorbidities (%)
16.5
—
Diet only (%)
17.7
—
Oral glucose lowering agents use only (%)
60.1
—
Insulin use (%)
22.1
—
Data as mean ± standard deviation or median (interquartile range). BMI: body mass index; HbA1c: glycated hemoglobin; SD: standard deviation. For continuous variables, we reported the mean + SD as well as the median and the IQR.
